Measuring dynamic changes in liver fibrosis in response to antiviral treatment

August 12, 2017

Share article

Recent studies have found that antiviral therapy can reverse liver fibrosis or even early cirrhosis caused by hepatitis B virus. However, they have mostly focused on the severity of, but not the dynamic changes in, fibrosis. The authors propose a new classification to evaluate these dynamic changes in the quality of fibrosis: predominantly progressive (thick/broad/loose/pale septa with inflammation), predominately regressive (delicate/thin/dense/splitting septa), and indeterminate. These represent an overall balance between progressive and regressive scarring. The authors then used this classification to evaluate 71 paired liver biopsies of chronic hepatitis B patients before and after entecavir-based therapy for 78 weeks. They found that progressive, indeterminate and regressive were observed in 58%, 29% and 13% of patients before treatment versus in 11%, 11% and 78% after treatment, respectively. Of the patients who showed predominantly regressive changes upon post-treatment liver biopsy, 53% still had fibrosis improvement of at least one Ishak stage and 45% displayed significant improvements in terms of Laennec substage, collagen percentage area and liver stiffness despite remaining in the same Ishak stage.

Read more here

Sun Y, Zhou J, Wang L, Wu X, Chen Y, et al. ISSN: Hepatology; 65(5): 1438-1450

Added: August 12, 2017